<?xml version="1.0" encoding="UTF-8"?>
<p id="p0215">We summarize the treatment of 327 pooled cases of severe cases with COVID-19 in 
 <xref rid="tbl2" ref-type="table">Table 2</xref>.
 <xref rid="bib1" ref-type="bibr">
  <sup>1</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib23" ref-type="bibr">
  <sup>23</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib24" ref-type="bibr">
  <sup>24</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib27" ref-type="bibr">
  <sup>27</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib28" ref-type="bibr">
  <sup>28</sup>
 </xref> In severe cases, 87.3% of patients (254/291) received antibiotic treatment, 61.5% (201/327) received antiviral treatment, 53.8% (176/327) received corticosteroid treatment, and 41.3% (115/278) received intravenous immunoglobulin. Only 8.4% of patients (23/274) received continuous renal replacement therapy. The mortality rate of the 327 pooled severe cases was 25.4% (83/327) (
 <xref rid="tbl2" ref-type="table">Table 2</xref>).
</p>
